Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics to effect 1-for-30 reverse stock split effective November 6, 2026

Neutral Impact 3 of 5 shareholder Written later

Jasper Therapeutics, Nasdaq-listed as JSPR, filed a charter amendment to carry out a 1-for-30 reverse stock split, which takes effect at 12:01 a.m. Eastern Time on November 6, 2026. Each stockholder's percentage ownership is unchanged apart from minor fractional-share adjustments, but the number of shares outstanding falls from about 33.3 million to about 1.1 million.

Key points

  • Ratio of 1-for-30 was set by the board on October 23, 2026, within the 1-for-15 to 1-for-35 range stockholders approved on September 30, 2026.
  • Shares outstanding fall from about 33.3 million to about 1.1 million; authorized shares stay at 490,000,000.
  • Cash will be paid in lieu of fractional shares based on the November 5, 2026 closing price.
  • Trading continues under JSPR on the Nasdaq Capital Market with new CUSIP 471871301.

The filing

CompanyJasper Therapeutics, Inc. (JSPR)
Form8-K, current report
Filed with the SECNov 4, 2026, 8:11 AM ET
Accession number0001213900-26-115751

Items reported: 3.03 Change to Shareholder Rights5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.